Highlights

  • ResMed CDI (ASX: RMD) reported fourth-quarter fiscal 2026 revenue growth, improved earnings measures and continued cash generation across its global healthcare operations.
  • AVITA Medical (ASX: AVH) reported higher second-quarter revenue, improved cash usage and increased full-year revenue guidance.
  • Both companies are focused on medical technology markets, with ResMed operating in sleep and breathing health while AVITA Medical develops advanced wound care solutions.
  • The updates reflect continued commercial activity and product adoption across international healthcare markets.

Australian healthcare investors continue to monitor companies with exposure to medical technology, where innovation, product adoption and international expansion remain key drivers of business performance. Two ASX-listed healthcare companies, ResMed CDI (ASX:RMD) and AVITA Medical (ASX:AVH), recently provided updates highlighting progress across their respective markets.

At the time of writing on 7 August 2026, ResMed was trading at $29.85, down 5.18% or $1.63 on the day, while AVITA Medical was trading at $1.51, up 17.97% or $0.23. The share price movements reflect market reactions following company announcements and broader investor assessment of healthcare sector developments.

ResMed reports continued revenue expansion and cash generation

ResMed reported fourth-quarter fiscal 2026 results showing revenue growth across its global sleep and breathing health business. The company recorded quarterly revenue of approximately US$1.5 billion, representing a 9% increase compared with the prior corresponding period.

For the full fiscal year, ResMed reported revenue of US$5.7 billion, representing 10% growth, while adjusted earnings measures also increased. The company reported annual diluted earnings per share growth, supported by higher revenue, margin improvements and ongoing operational execution.

The company’s sleep devices, masks and software solutions continued to contribute to overall performance. Sleep and breathing health revenue reached US$5.0 billion for the year, supported by demand across major geographic markets.

ResMed also reported operating cash flow of US$1.8 billion and free cash flow of US$1.6 billion during fiscal 2026. The company returned capital to shareholders through dividends and share repurchases, while continuing investment in technology and product development.

The company’s focus remains centred on connected healthcare solutions, digital health capabilities and expanding access to sleep-related treatments globally.

AVITA Medical advances wound care commercial strategy

AVITA Medical reported second-quarter fiscal 2026 results showing higher revenue and improving operating trends. The company recorded quarterly revenue of approximately US$21.7 million, representing an 18% increase year over year and a 13% improvement compared with the previous quarter.

Revenue growth was supported by its RECELL product portfolio, alongside contributions from Cohealyx and PermeaDerm. RECELL remained the company’s largest commercial product, generating approximately US$18.5 million in quarterly revenue.

AVITA Medical reported a gross profit margin of 81.9% during the quarter, while operating expenses declined compared with the previous corresponding period. The company also reduced net cash usage during the quarter, reflecting efforts to manage costs while expanding commercial activity.

Following the quarterly performance, AVITA Medical increased its full-year 2026 revenue guidance to between US$86 million and US$89 million. The company also indicated expectations to achieve cash flow breakeven during the fourth quarter of 2026.

The company continues to develop its position in acute wound care through technologies designed to support skin regeneration and wound management applications.

Healthcare technology remains a key ASX sector focus

The updates from ResMed and AVITA Medical highlight different segments within the healthcare market. ResMed operates at a larger global scale with established sleep and respiratory healthcare products, while AVITA Medical is focused on commercialising specialised wound care technologies.

Both companies demonstrate how healthcare businesses listed on the ASX are pursuing growth through product innovation, market expansion and improving operational efficiency.

ResMed’s results underline the importance of recurring demand and global healthcare infrastructure, while AVITA Medical’s update reflects progress in building commercial adoption for emerging medical technologies.

Conclusion

ResMed and AVITA Medical represent two different healthcare investment profiles, with one focused on established global healthcare solutions and the other on advancing specialised wound care technologies. Their latest updates provide insight into ongoing commercial execution, product demand and operational developments across the healthcare sector. Continued investor attention is likely to remain focused on how each company progresses its strategic objectives and responds to changing healthcare market conditions.